These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 37379361)

  • 41. Oncolytic adenovirus decreases the proportion of TIM-3
    Liikanen I; Basnet S; Quixabeira DCA; Taipale K; Hemminki O; Oksanen M; Kankainen M; Juhila J; Kanerva A; Joensuu T; Tähtinen S; Hemminki A
    J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35193929
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Tumor immunotherapy using adenovirus vaccines in combination with intratumoral doses of CpG ODN.
    Geary SM; Lemke CD; Lubaroff DM; Salem AK
    Cancer Immunol Immunother; 2011 Sep; 60(9):1309-17. PubMed ID: 21626029
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Synergistic effect of lymphotactin and interferon gamma-inducible protein-10 transgene expression in T-cell localization and adoptive T-cell therapy of tumors.
    Huang H; Xiang J
    Int J Cancer; 2004 May; 109(6):817-25. PubMed ID: 15027114
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Adenovirus vector-mediated in vivo gene transfer of OX40 ligand to tumor cells enhances antitumor immunity of tumor-bearing hosts.
    Andarini S; Kikuchi T; Nukiwa M; Pradono P; Suzuki T; Ohkouchi S; Inoue A; Maemondo M; Ishii N; Saijo Y; Sugamura K; Nukiwa T
    Cancer Res; 2004 May; 64(9):3281-7. PubMed ID: 15126371
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Oncolytic adenovirus expressing IL-23 and p35 elicits IFN-γ- and TNF-α-co-producing T cell-mediated antitumor immunity.
    Choi IK; Li Y; Oh E; Kim J; Yun CO
    PLoS One; 2013; 8(7):e67512. PubMed ID: 23844018
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Murine dendritic cells transfected with human GP100 elicit both antigen-specific CD8(+) and CD4(+) T-cell responses and are more effective than DNA vaccines at generating anti-tumor immunity.
    Yang S; Vervaert CE; Burch J; Grichnik J; Seigler HF; Darrow TL
    Int J Cancer; 1999 Nov; 83(4):532-40. PubMed ID: 10508491
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effective induction of therapeutic antitumor immunity by dendritic cells coexpressing interleukin-18 and tumor antigen.
    Xia D; Zheng S; Zhang W; He L; Wang Q; Pan J; Zhang L; Wang J; Cao X
    J Mol Med (Berl); 2003 Sep; 81(9):585-96. PubMed ID: 12937899
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Oncolytic adenovirus co-expressing IL-12 and IL-18 improves tumor-specific immunity via differentiation of T cells expressing IL-12Rβ2 or IL-18Rα.
    Choi IK; Lee JS; Zhang SN; Park J; Sonn CH; Lee KM; Yun CO
    Gene Ther; 2011 Sep; 18(9):898-909. PubMed ID: 21451575
    [TBL] [Abstract][Full Text] [Related]  

  • 49. In vivo programming of tumor antigen-specific T lymphocytes from pluripotent stem cells to promote cancer immunosurveillance.
    Lei F; Zhao B; Haque R; Xiong X; Budgeon L; Christensen ND; Wu Y; Song J
    Cancer Res; 2011 Jul; 71(14):4742-7. PubMed ID: 21628492
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Epidermal dendritic cells induce potent antigen-specific CTL-mediated immunity.
    Celluzzi CM; Falo LD
    J Invest Dermatol; 1997 May; 108(5):716-20. PubMed ID: 9129221
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Dual antigen target-based immunotherapy for prostate cancer eliminates the growth of established tumors in mice.
    Karan D; Dubey S; Van Veldhuizen P; Holzbeierlein JM; Tawfik O; Thrasher JB
    Immunotherapy; 2011 Jun; 3(6):735-46. PubMed ID: 21668311
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Recombinant adenovirus-transduced dendritic cell immunization in a murine model of central nervous system tumor.
    Broder H; Anderson A; Odesa SK; Kremen TJ; Liau LM
    Neurosurg Focus; 2000 Dec; 9(6):e6. PubMed ID: 16817689
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Cancer vaccine based on a combination of an infection-enhanced adenoviral vector and pro-inflammatory allogeneic DCs leads to sustained antigen-specific immune responses in three melanoma models.
    Fotaki G; Jin C; Kerzeli IK; Ramachandran M; Martikainen MM; Karlsson-Parra A; Yu D; Essand M
    Oncoimmunology; 2018; 7(3):e1397250. PubMed ID: 29399398
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Adenoviral gene transfer of interleukin 12 into tumors synergizes with adoptive T cell therapy both at the induction and effector level.
    Mazzolini G; Qian C; Narvaiza I; Barajas M; Borrás-Cuesta F; Xie X; Duarte M; Melero I; Prieto J
    Hum Gene Ther; 2000 Jan; 11(1):113-25. PubMed ID: 10646644
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Counteracting Immunosuppression in the Tumor Microenvironment by Oncolytic Newcastle Disease Virus and Cellular Immunotherapy.
    Schirrmacher V; van Gool S; Stuecker W
    Int J Mol Sci; 2022 Oct; 23(21):. PubMed ID: 36361831
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Loading of oncolytic vesicular stomatitis virus onto antigen-specific T cells enhances the efficacy of adoptive T-cell therapy of tumors.
    Qiao J; Wang H; Kottke T; Diaz RM; Willmon C; Hudacek A; Thompson J; Parato K; Bell J; Naik J; Chester J; Selby P; Harrington K; Melcher A; Vile RG
    Gene Ther; 2008 Apr; 15(8):604-16. PubMed ID: 18305577
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Adenovirus-mediated specific tumor tagging facilitates CAR-T therapy against antigen-mismatched solid tumors.
    Tang X; Li Y; Ma J; Wang X; Zhao W; Hossain MA; Yang Y
    Cancer Lett; 2020 Sep; 487():1-9. PubMed ID: 32454143
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Intracavitary adoptive transfer of IL-12 mRNA-engineered tumor-specific CD8
    Di Trani CA; Cirella A; Arrizabalaga L; Bella Á; Fernandez-Sendin M; Russo-Cabrera JS; Gomar C; Olivera I; Bolaños E; González-Gomariz J; Álvarez M; Etxeberria I; Palencia B; Teijeira Á; Melero I; Berraondo P; Aranda F
    Oncoimmunology; 2023; 12(1):2147317. PubMed ID: 36531687
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Intratumoral peptide injection enhances tumor cell antigenicity recognized by cytotoxic T lymphocytes: a potential option for improvement in antigen-specific cancer immunotherapy.
    Nobuoka D; Yoshikawa T; Takahashi M; Iwama T; Horie K; Shimomura M; Suzuki S; Sakemura N; Nakatsugawa M; Sadamori H; Yagi T; Fujiwara T; Nakatsura T
    Cancer Immunol Immunother; 2013 Apr; 62(4):639-52. PubMed ID: 23143746
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Oncolytic Adenovirus ORCA-010 Activates Proinflammatory Myeloid Cells and Facilitates T Cell Recruitment and Activation by PD-1 Blockade in Melanoma.
    Milenova I; Lopez Gonzalez M; Quixabeira DCA; Santos JM; Cervera-Carrascon V; Dong W; Hemminki A; van Beusechem VW; van de Ven R; de Gruijl TD
    Hum Gene Ther; 2021 Feb; 32(3-4):178-191. PubMed ID: 33470166
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.